Holen Sie sich die Stockscreener-App
238.32
0.76%
-1.75
Schlusskurs vom Vortag:
$240.07
Offen:
$238.38
24-Stunden-Volumen:
51,260
Relative Volume:
0.06
Marktkapitalisierung:
$15.46B
Einnahmen:
$4.44B
Nettoeinkommen (Verlust:
$29.49M
KGV:
-12,952.17
EPS:
-0.0184
Netto-Cashflow:
$1.19B
1W Leistung:
-2.98%
1M Leistung:
-7.14%
6M Leistung:
+28.50%
1J Leistung:
+85.36%
1-Tages-Spanne:
$236.00
$239.72
1-Wochen-Bereich:
$236.00
$249.00
52-Wochen-Spanne:
$123.88
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
238.12 | 15.58B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
522.22 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.14 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.10 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-02-27 | Eingeleitet | Barclays | Overweight |
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and a 17.28% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Stock Price Forecast. Should You Buy JAZZ? - StockInvest.us
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? - Yahoo Finance
Four September conference talks will include Jazz Pharmaceuticals - Stock Titan
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? - Eastern Progress
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth - insights.citeline.com
Jazz Pharmaceuticals PLC (JAZZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next - simplywall.st
Insider plans more Jazz (NASDAQ: JAZZ) share sales—but how big is this next trade? - Stock Titan
JAZZ Rises on Updated OS Results From Gastric Cancer Study - Yahoo Finance
Canaccord reiterates Jazz Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Nigeria
Jazz reports Phase III trial interim results for Ziihera combination - clinicaltrialsarena.com
Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032 - TradingView
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
No-Moat Jazz's Growth Supported by Strong Clinical Data for Ziihera and Expanding Opportunity - Morningstar
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares in 2026 - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans sale after 18,000 shares sold - Stock Titan
Positive Phase 3 Survival Results in HER2+ Advanced GEA – Jazz Pharmaceuticals - Oncodaily
Cancer drug decision could swing Jazz Pharmaceuticals' beatBizwomen - The Business Journals
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment - GuruFocus
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A 17% Upside Potential Lights Up Investor Interest - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock May Be Undervalued As FDA Cancer Approval Lands - simplywall.st
Jazz Pharmaceuticals prices $1.1B exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - TradingView
JAZZ PHARMACEUTICALS PLC : DEUTSCHE BANK RAISES TARGET PRICE TO $300 FROM $287 - webull.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032 - marketscreener.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering - Investing.com
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA - Yahoo Finance
Jazz Pharmaceuticals stock rises after FDA approves Ziihera By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD - Investing.com
Jazz Pharmaceuticals receives FDA approval for Ziihera HER2-positive GEA treatment - grafa.com
Jazz Pharma's fresh tune: New CEO wants to make longtime Bay Area drugmaker 'a true innovator' - The Business Journals
Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative - simplywall.st
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Announces $820 Million Acquisition of Actio Biosciences - Global Legal Chronicle
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jessica Merrill: Mid-Cap Biopharma's $1B-Plus Deal Surge Could Spawn the Next Amgen - finance.biggo.com
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):